Rockwell Medical (NASDAQ:RMTI) Releases Earnings Results, Misses Estimates By $0.01 EPS

Rockwell Medical (NASDAQ:RMTI) released its quarterly earnings results on Monday. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01), Zacks reports. Rockwell Medical had a positive return on equity of 8.55% and a negative net margin of 1.25%.

Rockwell Medical Price Performance

Shares of NASDAQ RMTI opened at $1.12 on Monday. Rockwell Medical has a fifty-two week low of $0.86 and a fifty-two week high of $5.15. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 2.00. The stock has a market capitalization of $38.11 million, a price-to-earnings ratio of -22.30 and a beta of 1.64. The business has a 50-day moving average of $1.23 and a 200-day moving average of $1.95.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their price target on Rockwell Medical from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, March 24th.

Insider Buying and Selling

In related news, major shareholder Larson Family Inve Irrevocable purchased 57,000 shares of the business’s stock in a transaction that occurred on Thursday, April 10th. The stock was acquired at an average cost of $1.07 per share, for a total transaction of $60,990.00. Following the completion of the purchase, the insider now owns 3,527,000 shares in the company, valued at approximately $3,773,890. This represents a 1.64% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 10,680 shares of company stock worth $11,552. Company insiders own 3.60% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.